DOCSLIB.ORG

Action of Antibiotics on Chloroplasts of Euglena Gracilis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Action of Antibiotics on Chloroplasts of Euglena Gracilis Journal qf General Microbioiogj?(I gp),71, 35-52 Printed in Great Britain 35 Are Plastids Derived from Prokaryotic Micro-organisms? Action of Antibiotics on Chloroplasts of Euglena gracilis By L. EBRINGER Department of Microbiology, Komensky University, Bratislava, Czechoslovakia (Accepted for publication I January 1972) SUMMARY Of 144 antibiotics examined with respect to their action on Euglena chloroplasts, 46 caused irreversible loss of plastids and most inhibited chlorophyll synthesis. These substances included structurally related compounds as well as degradation products of antibiotics. Antibiotics exhibiting bleaching activity were of two general types judged by their mechanisms of action in other systems : I. Inhibitors of DNA synthesis - anthramycin, edeine, porfiromycin, some mitomycins, myxin, nalidixic acid and its derivatives, novobiocin, primycin, rubi- flavin, sarkomycin and streptonigrin; 2. Inhibitors of protein synthesis - 29 antibiotics which carry a common mole- cular denominator in their structure (an aminohexose) and three antibiotics which lack aminosugar moieties : viomycin, streptogramin and pactamycin. Only these two types of antibiotics permanently eliminated chloroplasts ; anti- biotics classified as possessing other mechanisms of action were not effective. All these bleaching antibiotics inhibited replication of plastids in concentrations having no effect on normal Euglena division. A diluting-out of pathological plastids is the explanation of this ‘bleaching phenomenon’. INTRODUCTION Streptomycin was the first antibiotic found to induce the permanent loss of plastids in Euglena gracilis (Provasoli, Hutner & Schatz, I 948 ; Jirovec, 1949). For a long time strepto- mycin was considered as the only antibiotic bringing about this ‘bleaching effect’ in Euglena. However, in 1961 we observed that erythromycin exerted the same effect as streptomycin (Ebringer, I 96 I). Subsequently other antibiotics have been discovered which induce per- manent loss of chloroplasts in Euglena (Ebringer, 1962a, b, c, 1964, 1966, 1970, 1971; Ebringer, JurASek & Kada, 1967; Ebringer, Krkoska, MaEor, JurASek & Kada, 1967; Ebringer, Mego, JurASek & Kada, 1969; Zahalsky, Hutner, Keane & Burger, 1962; McCalla, 1962, 1965; Celmer & Ebringer, 1967; Lyman, 1967; McCalla & Baerg, 1969). Growing evidence supports the hypothesis of an exogenous origin for chloroplasts : (i) the presence of specific chloroplast DNA (Brawermann & Eisenstadt, 1964; Edelman, Schiff & Epstein, 1965); (ii) the presence in chloroplasts of 70s ribosomes which otherwise are found only in mitochondria and in prokaryotic micro-organisms (Boardman, Francki & Wildman, 1965; Kiintzel & Noll, 1967). These are different in many respects from 80 s ribosomes which are found in the cytoplasm of Euglena and all other plants and animals; (iii) the basically similar submicroscopical architecture of chloroplasts, mitochondria, bacteria and blue-green algae (Ris & Plaut, 1962). Euglena offers a convenient tool for studying the mechanisms of action of drugs or for antibiotic screening to find non-toxic drugs which attack the DNA of sensitive organisms 36 L. EBRINGER (Ebringer, 197I). The high sensitivity of chloroplasts and prokaryotic organisms towards antibacterial drugs suggests that in these two systems there is a common specific sensitive target (or targets) which is responsible for the damage or death of plastids and bacteria. METHODS Euglena gracilis strain z was grown in a proteose-peptone-tryptone medium (Mego, 1964). Stock cultures were grown in test tubes containing 10 ml of the medium, a 4-day culture at the end of logarithmic growth serving as inoculum. Usually the inoculum con- tained I 0 000 organisms/ml. Methods of cultivation, of determination of chlorophyll, of counting irreversibly bleached organisms, and of counting the chloroplasts per organism were as published by Ebringer, Neniec, Santovh & Foltinova (1970). In this paper we introduce a new expression, the ‘bleaching index’. The numerator in the bleaching index is a ratio of the killing concentration to the least bleaching concentration (in ,ug/ml) which causes the highest yo of permanently bleached cells. The denominator represents the difference between the killing concentration and the bleaching concentra- tion. I express to the following my deepest gratitude for gifts of antibiotics: Dr F. Arcamone, Farmitalia, Milan (daunomycin) ; Dr A. Aszales, The Squibb Institute for Medical Research, New Brunswick (rubiflavin) ; Dr V. Betina, Bratislava (citrinin, cyanein) ;Dr Zofia Borowska, New York (edeine); Dr W. D. Celmer, Chas. Pfizer & Co. (carbomycin, tylosin, oleando- mycin and its derivatives, erythromycin, anisomycin, streptidin, cladinose, erythralosamine, desosamine, triacetyldesosamine) ; Dr L. Delcambe, International Centre for Information on Antibiotics, LiCge (phleomycin, actinomycin D, cinerubin B, bluensomycin, hygromycin B, geodin, erdin, primycin, anthramycin, stendomycin); Dr R. Donovick, The Squibb Institute for Medical Research, New Brunswick (methymycin); Dr J. Greenberg, Palo Alto Medical Research Foundation (carzinophillin) ; Dr L. Hanka, The Upjohn Company, Kalamazoo (amicetin and its derivatives, lincomycin, clindamycin) ; Dr R. Hochster, Cell Biology Institute, Canadian Department of Agriculture, Ottawa (myxin) ; Dr J. Hoogerheide, Mycofarm, Delft (pimaricin); Dr K. Kagiwada, Kaken Chemical Co. Ltd, Tokyo (dihydro- deoxystreptomycin); Dr G. Lemonofides, The Winthrop Products Co., Surbiton, Surrey (nalidixic acid and its derivatives); Dr 0. Gonqalves de Lima, Tnstituto de Antibioticos, Recife, Brazil (lapachol); Dr H. E. Machamer, Parke-Davis Co., Detroit (viridogrisein, streptimidone); Dr T. J. McBride, Chas. Pfizer & Co. (streptonigrin, mithramycin); Dr J. L. Mego, Biology Department, University of Alabama (gougerotin); Dr J. Nakaya, Kyowa Hakko Kogyo Co. Ltd, Tokyo (mitomycins A, B, C, N-methylmitomycin); Dr N. Otake, The University of Tokyo (blasticidin S); Dr V. Prelog, Zurich (angolamycin, lanka- mycin, picromycin, rifamycin B); Dr F. M. Rottman, Michigan State University (cordy- cepin) ; Dr 2. kehBEek, Czechoslovak Academy of Sciences, Prague (antimycin A) ; Dr J. C. Sylvester, Abbott Laboratories, Chicago (hydroxystreptomycin, dihydroxystreptomycin, spectinomycin); Dr H. Thrum, Jena (streptothricin) ; Dr D. Vazquez, Madrid (chloram- phenicols, streptogramin) ; Dr F. P. Willey, The Upjohn Co., Kalamazoo (tubercidin, nogalamycin and its derivatives, streptovitacin A, cycloheximide, cytosin arabinoside, decoyinine, pactamycin, pactamycate, porfiromycin) ; Dr W. K. Woo, Parke-Davis Co., Detroit (chalcomycin); Dr A. Zugaza, Antibioticos, S.A. Madrid (kitasamycin and its derivatives, dihydrostreptomycin). Antibiotics not listed above were purchased from com- mercial sources. Chloroplasts of Euglena gracilis 37 Table I. The action of inhibitors of nucleic acids and of synthesis of purine and pyrimidine nucleotides on Euglena chloroplasts Bleached cells 10 white Least on the 9th colonies after bleaching Colour of day after 10 subcultur- concn (pglml) cultures on plating pro- ing gave the Killing causing the the 7th day duced by following no. concn highest % of after addition ‘least concn’ of bleached No. Antibiotic (pglml) bleached cells of antibiotics (%) subcultures I Anthram ycin 80 60 W 87 9 2 Edein 5 4 PG 27 5 3 Mitomycin A I0 NB - - - 4 Mitomycin B 60 50 PG 40 8 5 Mitomycin C 30 NB - - - 6 N-Methyl mitomycin 50 40 PG 55 9 7 Porfiromycin I20 80 PG 72 9 8 Myxin 200 I0 W I00 I0 9 Nalidixic acid 1-ethyl-7-methyl- 2 000 500 W I00 I0 I :8-naphtyridone-4-one+ carboxylic acid I0 Ethyl(7-methyl-I :S-naphtyridone- 700 I0 +one-3-carboxylate) I1 Ethyl(1-ethyl-7-methyl-I:8- 700 5 naphtyridone-4-one-3-carboxylate) 12 5-Nitrofurfuril ester of nalidixic 20 - acid 13 Novobiocin 800 500 I0 14 Phleomycin 0.I NB - I5 Primycin 20 19 6 16 RubiRavin 220 30 I0 17 Sarcomycin 15000 I0000 9 I8 Streptonigrin I20 I00 9 19 Carzinophillin I0 NB - 20 Actinomycin D 15 NB - 21 Actinomycin C 300 NB - 22 Nogalamycin 200 NB - 23 Nogalarol 200 NB - - 24 Nogalarene 200 NB 25 7-U-methylnogalarol 200 NB - 26 Cinerubin B 200 NB - - 27 Daunomycin 500 NB NB - 28 Mi thramycin 50 - 29 Echinomycin 1.5 NB 30 Cordycepin 200 NB - 31 Tubercidin 1000 NB - Formycin 200 NB - 32 - 33 Cytosin arabinoside I000 NB Decoyinine I000 NB - 34 - 35 Psicofuranine I000 NB The following abbreviations will be used: NB, no bleaching activity; G, green colonies or cultures; W, white colonies or cultures; PG, pale green colonies or cultures. RESULTS Table I shows that among inhibitors of nucleic acid synthesis only those antibiotics which attack DNA synthesis exhibited a bleaching effect. Among the 19 antibiotics tested (Table I, Compound no. I to 19) 14 exerted bleaching activity. Those exhibiting an especially favourable bleaching index were myxin, rubiflavin and nalidixic acid. Derivatives of nalidixic acid (Compound no. 10 to 12) had either no bleaching activity or lower activity than the darent substance. Phleomycin, mitomycins A and C and carzinophillin lacked bleaching effect. These compounds, especially phleomycin, had a high toxicity against Euglena. No antibiotic which inhibited RNA synthesis or purine and pyrimidine nucleotides synthesis (Table I, Compound no. 20 to 35) showed permanent bleaching activity, even in nearly lethal concentrations. Table 2 concerns inhibitors of protein synthesis. Most of this group consists of structurally 38 L. EBRINGER Table 2. The action of inhibitors of protein synthesis and some antibiotics structurallr
Load more

Recommended publications
  • Allosteric Drug Transport Mechanism of Multidrug Transporter Acrb
    ARTICLE https://doi.org/10.1038/s41467-021-24151-3 OPEN Allosteric drug transport mechanism of multidrug transporter AcrB ✉ Heng-Keat Tam 1,3,4 , Wuen Ee Foong 1,4, Christine Oswald1,2, Andrea Herrmann1, Hui Zeng1 & ✉ Klaas M. Pos 1 Gram-negative bacteria maintain an intrinsic resistance mechanism against entry of noxious compounds by utilizing highly efficient efflux pumps. The E. coli AcrAB-TolC drug efflux pump + 1234567890():,; contains the inner membrane H /drug antiporter AcrB comprising three functionally inter- dependent protomers, cycling consecutively through the loose (L), tight (T) and open (O) state during cooperative catalysis. Here, we present 13 X-ray structures of AcrB in inter- mediate states of the transport cycle. Structure-based mutational analysis combined with drug susceptibility assays indicate that drugs are guided through dedicated transport chan- nels toward the drug binding pockets. A co-structure obtained in the combined presence of erythromycin, linezolid, oxacillin and fusidic acid shows binding of fusidic acid deeply inside the T protomer transmembrane domain. Thiol cross-link substrate protection assays indicate that this transmembrane domain-binding site can also accommodate oxacillin or novobiocin but not erythromycin or linezolid. AcrB-mediated drug transport is suggested to be allos- terically modulated in presence of multiple drugs. 1 Institute of Biochemistry, Goethe-University Frankfurt, Frankfurt am Main, Germany. 2 Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, UK. 3Present
    [Show full text]
  • Combination of Minocycline and Rifampicin Against Methicillin- and Gentamicin-Resistant Staphylococcus Aureus
    J Clin Pathol: first published as 10.1136/jcp.34.5.559 on 1 May 1981. Downloaded from J Clin Pathol 1981 ;34:559-563 Combination of minocycline and rifampicin against methicillin- and gentamicin-resistant Staphylococcus aureus E YOURASSOWSKY, MP VAN DER LINDEN, MJ LISMONT, F CROKAERT From the H6pital Universitaire Brugmann, Service de Biologie Clinique, 1020 Bruxelles, Belgique SUMMARY Methicillin- and gentamicin-resistant Staphylococcus aureus may remain sensitive to minocycline and to rifampicin. A study of growth curves has shown that at inhibitory concentrations (0-4 ,ug/ml), minocycline prevents the development of mutants resistant to rifampicin. Staphylococcus aureus resistant to methicillin and strains of different phage type were selected for this gentamicin is responsible for an increasing number of investigation. hospital infections, some of which are severe.1-7 A number of treatments have been suggested although Microbial strains vancomycin is often the only major antibiotic which Minocycline HCL (Cyanamid Benelux, batch no is active against these strains. However, it is necessary 7116B-172). Rifampicin (Lepetit, batch no P/4) copyright. to assess the effect of the "second choice" antibiotics. (solution in dimethyl formamide). The MICs of The risk of rapid development of resistance to minocycline (tube dilution method in Mueller Hinton rifampicin is well known,8 9 and in spite of the medium, inoculum 106 micro-organisms/ml) were excellent penetration particularly in polymor- 0-2 ,ug/ml for all the strains. Rifampicin showed phonuclear cells of this antibiotic,10 11 its use alone is minimal inhibitory activity in liquid medium up to contraindicated. Minocycline is active against Staph a concentration of 0-01 ,ug/ml.
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • Pharmaceutical Microbiology Table of Contents
    TM Pharmaceutical Microbiology Table of Contents Pharmaceutical Microbiology ������������������������������������������������������������������������������������������������������������������������ 1 Strains specified by official microbial assays ������������������������������������������������������������������������������������������������ 2 United States Pharmacopeia (USP) �������������������������������������������������������������������������������������������������������������������������������������������2 European Pharmacopeia (EP) Edition 8�1 ���������������������������������������������������������������������������������������������������������������������������������5 Japanese Pharmacopeia (JP) ������������������������������������������������������������������������������������������������������������������������������������������������������7 Strains listed by genus and species �������������������������������������������������������������������������������������������������������������10 ATCC provides research and development tools and reagents as well as related biological material management services, consistent with its mission: to acquire, authenticate, preserve, develop, and distribute standard reference THE ESSENTIALS microorganisms, cell lines, and related materials for research in the life sciences� OF LIFE SCIENCE For over 85 years, ATCC has been a leading authenticate and further develop products provider of high-quality biological materials and services essential to the needs of basic and standards to the life
    [Show full text]
  • 1028 Subpart A—Susceptibility Discs
    § 460.1 21 CFR Ch. I (4±1±96 Edition) 460.137 Methicillin concentrated stock solu- Neomycin: 30 mcg. tions for use in antimicrobial suscepti- Novobiocin: 30 mcg. bility test panels. Oleandomycin: 15 mcg. 460.140 Penicillin G concentrated stock so- Penicillin G: 10 units. lutions for use in antimicrobial suscepti- Polymyxin B: 300 units. bility test panels. Rifampin: 5 mcg. 460.146 Tetracycline concentrated stock so- Streptomycin: 10 mcg. lutions for use in antimicrobial suscepti- Tetracycline: 30 mcg. bility test panels. Tobramycin: 10 mcg. 460.149 Tobramycin concentrated stock so- Vancomycin: 30 mcg. lutions for use in antimicrobial suscepti- bility test panels. The standard discs used to determine 460.152 Trimethoprim concentrated stock the potency shall be made of paper as solutions for use in antimicrobial suscep- described in § 460.6(d). Each antibiotic tibility test panels. compound used to impregnate such 460.153 Sulfamethoxazole concentrated stock solutions for use in antimicrobial standard discs shall be equilibrated in susceptibility test panels. terms of the working standard des- ignated by the Commissioner for use in AUTHORITY: Sec. 507 of the Federal Food, determining the potency or purity of Drug, and Cosmetic Act (21 U.S.C. 357). such antibiotic. SOURCE: 39 FR 19181, May 30, 1974, unless (b) Packaging. The immediate con- otherwise noted. tainer shall be a tight container as de- fined by the U.S.P. and shall be of such Subpart AÐSusceptibility Discs composition as will not cause any change in the strength, quality, or pu- § 460.1 Certification procedures for an- rity of the contents beyond any limit tibiotic susceptibility discs.
    [Show full text]
  • TYLOSIN First Draft Prepared by Jacek Lewicki, Warsaw, Poland Philip T
    TYLOSIN First draft prepared by Jacek Lewicki, Warsaw, Poland Philip T. Reeves, Canberra, Australia and Gerald E. Swan, Pretoria, South Africa Addendum to the monograph prepared by the 38th Meeting of the Committee and published in FAO Food and Nutrition Paper 41/4 IDENTITY International nonproprietary name: Tylosin (INN-English) European Pharmacopoeia name: (4R,5S,6S,7R,9R,11E,13E,15R,16R)-15-[[(6-deoxy-2,3-di-O-methyl- β-D-allopyranosyl)oxy]methyl]-6-[[3,6-dideoxy-4-O-(2,6-dideoxy-3- C-methyl-α-L-ribo-hexopyranosyl)-3-(dimethylamino)-β-D- glucopyranosyl]oxy]-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-(2- oxoethyl)oxacyclohexadeca-11,13-diene-2,10-dione IUPAC name: 2-[12-[5-(4,5-dihydroxy-4,6-dimethyl-oxan-2-yl)oxy-4- dimethylamino-3-hydroxy-6-methyl-oxan-2-yl]oxy-2-ethyl-14- hydroxy-3-[(5-hydroxy-3,4-dimethoxy-6-methyl-oxan-2- yl)oxymethyl]-5,9,13-trimethyl-8,16-dioxo-1-oxacyclohexadeca-4,6- dien-11-yl]acetaldehyde Other chemical names: 6S,1R,3R,9R,10R,14R)-9-[((5S,3R,4R,6R)-5-hydroxy-3,4-dimethoxy- 6-methylperhydropyran-2-yloxy)methyl]-10-ethyl-14-hydroxy-3,7,15- trimethyl-11-oxa-4,12-dioxocyclohexadeca-5,7-dienyl}ethanal Oxacyclohexadeca-11,13-diene-7-acetaldehyde,15-[[(6-deoxy-2,3- dimethyl-b-D-allopyranosyl)oxy]methyl]-6-[[3,6-dideoxy-4-O-(2,6- dideoxy-3-C-methy-a-L-ribo-hexopyranosyl)-3-(dimethylamino)-b-D- glucopyranosyl]oxy]-16-ethyl-4-hydroxy-5,9,13-trimethyl-2,10- dioxo-[4R-(4R*,5S*,6S*,7R*,9R*,11E,13E,15R*,16R*)]- Synonyms: AI3-29799, EINECS 215-754-8, Fradizine, HSDB 7022, Tilosina (INN-Spanish), Tylan, Tylocine, Tylosin, Tylosine, Tylosine (INN-French), Tylosinum (INN-Latin), Vubityl 200 Chemical Abstracts System number: CAS 1401-69-0 Structural formula: Tylosin is a macrolide antibiotic representing a mixture of four tylosin derivatives produced by a strain of Streptomyces fradiae (Figure 1).
    [Show full text]
  • Backyard Chickens in the Consult Room
    BACKYARD CHICKENS IN THE CONSULT ROOM Michael Cannon BVSc, MACVSc, Grad DipEd Cannon and Ball Veterinary Surgeons 461 Crown Street, West Wollongong In recent years clients are arriving with their chickens and but their expectations have changed ‐ they are wanting them treated as pets rather than as production animals. This means you cannot use common poultry techniques for diagnosis, such as slaughter and post‐mortem. The aim of this short presentation is to give you some tips on what I have found help me deal with this kind of patient. Common Breeds Clients often know the breed of their chickens and they become disappointed if you do not. They feel they know the breed so they know more than you. This embarrassing situation is simply avoided by the receptionist or nurse asking the question and recording the breed on your file. The common breeds that were the basis of many of the common backyard birds and the poultry industry in Australia are: Australorp and the White Leghorn. There are many other commonly encountered Show Poultry breeds such as : Silkie Bantam; White Sussex; Araucana, Ancona; Pekin (the true bantam): ISA Brown; Australian Game; Cochin; Barnevelder; White Polish; Minorca; Rhode Island Red and New Hampshire. Some Quick Facts •Many Backyard chickens live approximately 8‐10 years •They have only three good productive years • 70% of the cost of raising chickens is spent on feed •In monogastric animals, like chickens, energy comes mainly from carbohydrates and fats since fibre containing cellulose cannot be digested •White eggs are laid by chickens with white ear lobes, while brown eggs are laid by chickens with red ear lobes.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • E3 Appendix 1 (Part 1 of 2): Search Strategy Used in MEDLINE
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (part 1 of 2): Search strategy used in MEDLINE # Searches 1 exp *anti-bacterial agents/ or (antimicrobial* or antibacterial* or antibiotic* or antiinfective* or anti-microbial* or anti-bacterial* or anti-biotic* or anti- infective* or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or clindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).kf,kw,ti. or (antimicrobial or antibacterial or antiinfective or anti-microbial or anti-bacterial or anti-infective or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or c lindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).ab. /freq=2 2 alamethicin/ or amdinocillin/ or amdinocillin pivoxil/ or amikacin/ or amoxicillin/ or amphotericin b/ or ampicillin/ or anisomycin/ or antimycin a/ or aurodox/ or azithromycin/ or azlocillin/ or aztreonam/ or bacitracin/ or bacteriocins/ or bambermycins/ or bongkrekic acid/ or brefeldin a/ or butirosin sulfate/ or calcimycin/ or candicidin/ or capreomycin/ or carbenicillin/ or carfecillin/ or cefaclor/ or cefadroxil/ or cefamandole/ or cefatrizine/ or cefazolin/ or cefixime/ or cefmenoxime/ or cefmetazole/ or cefonicid/ or cefoperazone/
    [Show full text]
  • WO 2016/120258 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2016/120258 A l 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/20 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 16/05 1545 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 26 January 2016 (26.01 .2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 264/MUM/2015 27 January 2015 (27.01 .2015) IN kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: JANSSEN PHARMACEUTICA NV TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).
    [Show full text]
  • Sales of Veterinary Antimicrobial Agents in 29 European Countries in 2014
    Sales of veterinary antimicrobial agents in 29 European countries in 2014 Trends across 2011 to 2014 Sixth ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role • publishes impartial and comprehensible information about medicines and their use; The European Medicines Agency is the European Union body responsible for coordinating the existing scientific resources • develops best practice for medicines evaluation and put at its disposal by Member States for the evaluation, supervision in Europe, and contributes alongside the supervision and pharmacovigilance of medicinal products. Member States and the European Commission to the harmonisation of regulatory standards at the international The Agency provides the Member States and the institutions level. of the European Union (EU) and the European Economic Area (EEA) countries with the best-possible scientific advice Guiding principles on any questions relating to the evaluation of the quality, safety and efficacy of medicinal products for human or • We are strongly committed to public and animal health. veterinary use referred to it in accordance with the provisions of EU legislation relating to medicinal products. • We make independent recommendations based on scien- tific evidence, using state-of-the-art knowledge and The founding legislation of the Agency is Regulation (EC) expertise in our field. No 726/2004. • We support research and innovation to stimulate the Principal activities development of better medicines. Working with the Member States and the European Commission as partners in a European medicines network, the European • We value the contribution of our partners and stakeholders Medicines Agency: to our work.
    [Show full text]